These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38539518)

  • 61. DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis.
    Rong G; Yi Z; Ma F; Guan Y; Xu Y; Li L; Xu B
    Ann Transl Med; 2021 Feb; 9(3):220. PubMed ID: 33708847
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Next-Generation Sequencing and Triple-Negative Breast Cancer: Insights and Applications.
    Tierno D; Grassi G; Scomersi S; Bortul M; Generali D; Zanconati F; Scaggiante B
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298642
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
    Naqvi MF; Vo HH; Vining D; Tsimberidou AM
    Ther Adv Med Oncol; 2021; 13():17588359211001538. PubMed ID: 33995588
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
    Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
    Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Targeted next generation sequencing of circulating tumor DNA provides prognostic information for management in breast cancer patients.
    Shim H; Kwon MJ; Park IH; Kim MK; Cho EH; Lee J; Lee ST; Sim SH; Lee KS; Kim YH; Kim SK; Lee ES; Kong SY
    Ann Transl Med; 2022 Jan; 10(2):28. PubMed ID: 35282050
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
    Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
    Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
    [TBL] [Abstract][Full Text] [Related]  

  • 67. TP53 mutation and MET amplification in circulating tumor DNA analysis predict disease progression in patients with advanced gastric cancer.
    Li J; Li Z; Ding Y; Xu Y; Zhu X; Cao N; Huang C; Qin M; Liu F; Zhao A
    PeerJ; 2021; 9():e11146. PubMed ID: 33959414
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data.
    Zhao S; Cong X; Liu Z
    Biomed Res Int; 2021; 2021():8817898. PubMed ID: 33997043
    [TBL] [Abstract][Full Text] [Related]  

  • 69. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
    Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
    BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Current situation and prospect of breast cancer liquid biopsy].
    Zhou B; Xin L; Xu L; Ye JM; Liu YH
    Zhonghua Wai Ke Za Zhi; 2018 Feb; 56(2):106-109. PubMed ID: 29397622
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mutated
    Kampel L; Feldstein S; Tsuriel S; Hannes V; Carmel Neiderman NN; Horowitz G; Warshavsky A; Leider-Trejo L; Hershkovitz D; Muhanna N
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759818
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy in metastatic breast cancer.
    Bortolini Silveira A; Bidard FC; Tanguy ML; Girard E; Trédan O; Dubot C; Jacot W; Goncalves A; Debled M; Levy C; Ferrero JM; Jouannaud C; Rios M; Mouret-Reynier MA; Dalenc F; Hego C; Rampanou A; Albaud B; Baulande S; Berger F; Lemonnier J; Renault S; Desmoulins I; Proudhon C; Pierga JY
    NPJ Breast Cancer; 2021 Sep; 7(1):115. PubMed ID: 34504096
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patients.
    Kim S; Kim S; Kim SH; Jung EH; Suh KJ; Kim YJ; Kwon NJ; Kim H; Chung JH; Lee JS
    Transl Lung Cancer Res; 2023 Jun; 12(6):1185-1196. PubMed ID: 37425402
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical significance of the mutational landscape and fragmentation of circulating tumor DNA in renal cell carcinoma.
    Yamamoto Y; Uemura M; Fujita M; Maejima K; Koh Y; Matsushita M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nakagawa H; Nonomura N
    Cancer Sci; 2019 Feb; 110(2):617-628. PubMed ID: 30536551
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
    Turner NC; Kingston B; Kilburn LS; Kernaghan S; Wardley AM; Macpherson IR; Baird RD; Roylance R; Stephens P; Oikonomidou O; Braybrooke JP; Tuthill M; Abraham J; Winter MC; Bye H; Hubank M; Gevensleben H; Cutts R; Snowdon C; Rea D; Cameron D; Shaaban A; Randle K; Martin S; Wilkinson K; Moretti L; Bliss JM; Ring A
    Lancet Oncol; 2020 Oct; 21(10):1296-1308. PubMed ID: 32919527
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma.
    Guan T; Zhang M; Liu X; Li J; Xin B; Ren Y; Yang Y; Wang H; Zhao M; Huang Y; Guo X; Du J; Qian W; Su L
    Front Oncol; 2022; 12():1003957. PubMed ID: 36465410
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
    Liu B; Yi Z; Guan Y; Ouyang Q; Li C; Guan X; Lv D; Li L; Zhai J; Qian H; Xu B; Ma F; Zeng Y
    Cancer Med; 2022 Jul; 11(14):2767-2778. PubMed ID: 35393784
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer.
    Turner NC; Swift C; Jenkins B; Kilburn L; Coakley M; Beaney M; Fox L; Goddard K; Garcia-Murillas I; Proszek P; Hall P; Harper-Wynne C; Hickish T; Kernaghan S; Macpherson IR; Okines AFC; Palmieri C; Perry S; Randle K; Snowdon C; Stobart H; Wardley AM; Wheatley D; Waters S; Winter MC; Hubank M; Allen SD; Bliss JM;
    Ann Oncol; 2023 Feb; 34(2):200-211. PubMed ID: 36423745
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis.
    Benesova L; Ptackova R; Halkova T; Semyakina A; Svaton M; Fiala O; Pesek M; Minarik M
    Pathol Oncol Res; 2022; 28():1610308. PubMed ID: 35837614
    [No Abstract]   [Full Text] [Related]  

  • 80. Tumor-Informed Approach Improved ctDNA Detection Rate in Resected Pancreatic Cancer.
    Watanabe K; Nakamura T; Kimura Y; Motoya M; Kojima S; Kuraya T; Murakami T; Kaneko T; Shinohara Y; Kitayama Y; Fukuda K; Hatanaka KC; Mitsuhashi T; Pittella-Silva F; Yamaguchi T; Hirano S; Nakamura Y; Low SK
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232820
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.